Orphan Drug Designation by the FDA is highly sought after in the biotech industry as it provides benefits such as market exclusivity, tax credits, and assistance with clinical research. If Tiziana's application is successful, it could significantly enhance the commercial potential of intranasal Foralumab, leading to increased investor interest and potentially a higher stock price in the short term.